Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

CYTX 6th International Conference on Cell Therapy for Cardiovascular Disease Presentation


Published on

Presented by Brad Conlan, Director of Regenerative Medicine on Thursday, January 20 at a Product Development Panel at the 6th International Conference on Cell Therapy for Cardiovascular Disease

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

CYTX 6th International Conference on Cell Therapy for Cardiovascular Disease Presentation

  1. 1. Celution One: Next Generation Innovation <br />Brad Conlan <br />Director, Regenerative Medicine <br />Business Unit<br />
  2. 2. Safe Harbor Statement<br />This presentation may contain certain ‘forward-looking statements’. All<br />statements other statements, than statements of historical fact, that address activities, events or developments that we intend, expect, project,<br />believe or anticipate will or may occur in the future are forward-looking<br />statements. Such statements are based upon certain assumptions and<br />assessments made by our management in light of their experience and<br />their perception of historical trends, current conditions, expected future<br />developments and other factors they believe to be appropriate.<br />The forward-looking statements included in this presentation are also<br />subject to a number of material risks and uncertainties. We caution<br />investors not to place undue reliance on the forward-looking statements<br />contained in this presentation. We would advise reading our annual report filed with the United States Securities and Exchange Commission on Form 10-K for a more detailed description of these risks.<br />
  3. 3. Adipose Derived Regenerative Cells (ADRCs)<br />Liposuction<br />Processing<br />Adipose Derived Regenerative Cells<br />Adipose Tissue<br /><ul><li>Adipocytes
  4. 4. Adult stem cells
  5. 5. Endothelial cells
  6. 6. Vasc. smooth muscle cells
  7. 7. Tissue resident macrophages
  8. 8. Perivascular cells
  9. 9. ……..
  10. 10. Adipocytes
  11. 11. Adult stem cells
  12. 12. Endothelial cells
  13. 13. Vasc. smooth muscle cells
  14. 14. Tissue resident macrophages
  15. 15. Perivascular cells
  16. 16. ……..</li></li></ul><li>Separate,<br />process <br />and deliver<br />1.5 hours<br />Return cells/tissue <br />to same patient<br />Real-Time, Point-of-Care Autologous Cell Therapy <br />Present – Celution Clinical Relevance<br />Harvest donor <br />tissue<br />Harvest tissue and return to <br />patient in same procedure<br />
  17. 17. Present – Celution Product Generations<br />For Delivery of ADRCs<br />Real-time, point-of-care access to adult adipose-derived stem and regenerative cells (ADRCs)<br />Standardizes the extraction, washing and concentration of ADRCs for present or future clinical use.<br />Celution® 805/CRS <br />Consumable Set<br />Celase™ 835 / CRS Reagent<br />Celution ® 800/CRS Device<br />*Currently not available in the United States<br />
  18. 18. Present – Celution Clinical Relevance<br />• CE marked<br />• Clinical Applications<br /> Breast Reconstruction<br /> Breast Asymmetry<br /> Soft Tissue Wasting<br /> Crohn’s Fistula<br />Celution ® 800/CRS Device<br />*Currently not available in the United States<br />
  19. 19. Scalability – Olympus Manufacturing Partnership<br />Joint Venture (2005)<br />Next generation<br />
  20. 20. Celution® Onesystem<br />Key Features<br />• Automated<br />• Closed System<br />• Real-Time<br />• Intra-operative<br />• Onboard Liposuction System<br />• Barcode Scanning<br />• Multilingual Interactive Display<br />*Currently not available in the United States<br />
  21. 21. Celution® One System<br />Key Benefits<br />*Currently not available in the United States<br />
  22. 22. European AMI Pivotal Trial<br /><ul><li>ADVANCE will use Celution® One
  23. 23. Randomized, placebo controlled, double-blind trial
  24. 24. Enrollment: Up to 360 patients with ST-elevation myocardial infarction
  25. 25. Up to 35 European centers</li></li></ul><li>Thank You<br />